Metformin Safety and Efficacy in Osteoarthritis.

Launched by MOSTAFA BAHAA · Jan 20, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the safety and effectiveness of a medication called Metformin for treating knee osteoarthritis (OA), a common condition that causes pain and can significantly affect daily activities. The trial is currently recruiting participants aged between 30 and 60 years who have been diagnosed with moderate to severe knee OA, based on X-ray results. This trial aims to find out if Metformin can help manage the symptoms of OA and potentially slow down the progression of the disease.

If you or someone you know is interested in participating, it’s important to note that individuals with certain medical conditions or those who have taken specific treatments recently may not be eligible. Participants can expect to receive the study medication and will be monitored throughout the trial to assess their response to the treatment. This research is crucial because, at present, there are few options available to change the course of osteoarthritis, and finding effective treatments could greatly improve the quality of life for many people.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Primary osteoarthritis Patients recruited were between 30 to 60 years of age.
• • X-ray confirmed Kellgren-Lawrence grade II or III severity primary tibiofemoral OA according to the American College of Rheumatology criteria.
• Exclusion Criteria:
• • Patients with age less than 30 years or more than 60 years Patients Presented with active concomitant gastroduodenal disorders, hepatic and renal impairment within last 30 days prior to receiving the study drug Patients Were diagnosed to have any inflammatory arthritis, gout or acute trauma of the knee, hip or spine; accompanying OA of the hip of sufficient severity to interfere with the functional assessment of the knee Patients had previous or ongoing treatment with oral SYSDOA (e.g., glucosamine sulphate, chondroitin sulphate, diacerein, piascledine), anti-depressants, tranquillisers, antacids or antibiotics; were having active cardiac lesion or hypertension, were pregnant females and those who were planning their pregnancy during the study Patients having a known hypersensitivity to the used medications Patients have persistent diarrhoea or laxative use; severe gastrointestinal disorders, severe obesity, severe parenchymal organ disease, or anaemia (haemoglobin\< 10.0 g/ dl or haematocrit \< 30%).
• • Patients who received oral, intramuscular, intraarticular or soft tissue injections of corticosteroids within last eight weeks before receiving the first dose of the study medication or had undergone joint lavage and arthroscopic procedures in the previous 6 months, were also excluded.